Diagnostics Saves Roche From Q1 Difficulties

In its first quarter 2021 sales earnings report, Roche highlighted the strength of its diagnostics business as biosimilars cannibalize its pharmaceutical revenues.

Placer

The growth of Roche’s diagnostics division flipped the decline observed since 2017, accelerated primarily by the COVID-19 pandemic as it released a plethora of rapid testing kits. 

Roche announced its first quarter earnings on 21 April. Group sales were up 3% at constant exchange rates. This was,...

More from In Vitro Diagnostics

More from Diagnostics